Soligenix, Inc.

LSE:0A6I Stock Report

Market Cap: US$8.4m

Soligenix Valuation

Is 0A6I undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A6I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A6I's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A6I's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A6I?

Key metric: As 0A6I is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A6I. This is calculated by dividing 0A6I's market cap by their current revenue.
What is 0A6I's PS Ratio?
PS Ratio23x
SalesUS$364.18k
Market CapUS$8.38m

Price to Sales Ratio vs Peers

How does 0A6I's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A6I vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.8x
APTA Aptamer Group
7.1xn/aUK£6.1m
GENF Genflow Biosciences
10.1xn/aUK£6.0m
VRCI Verici Dx
2.4x78.8%UK£8.2m
PBX ProBiotix Health
3.7xn/aUK£7.9m
0A6I Soligenix
23x44.2%US$8.4m

Price-To-Sales vs Peers: 0A6I is expensive based on its Price-To-Sales Ratio (23x) compared to the peer average (6.2x).

Price to Sales Ratio vs Industry

How does 0A6I's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.6x21.0%US$561.69m
TRX Tissue Regenix Group
1.6x15.1%US$50.93m
VRCI Verici Dx
2.4x78.8%US$10.27m
0A6I 23.0xIndustry Avg. 7.9xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A6I is expensive based on its Price-To-Sales Ratio (23x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0A6I's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A6I PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23x
Fair PS Ratio9.9x

Price-To-Sales vs Fair Ratio: 0A6I is expensive based on its Price-To-Sales Ratio (23x) compared to the estimated Fair Price-To-Sales Ratio (9.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A6I forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.41
US$22.50
+559.6%
55.6%US$35.00US$10.00n/a2
Nov ’25US$3.66
US$22.50
+514.8%
55.6%US$35.00US$10.00n/a2
Oct ’25US$3.91
US$22.50
+475.7%
55.6%US$35.00US$10.00n/a2
Sep ’25US$3.35
US$22.50
+571.6%
55.6%US$35.00US$10.00n/a2
Aug ’25US$4.23
US$41.50
+882.2%
15.7%US$48.00US$35.00n/a2
Jul ’25US$2.49
US$40.00
+1,506.4%
20.0%US$48.00US$32.00n/a2
Jun ’25US$5.20
US$40.00
+669.2%
20.0%US$48.00US$32.00n/a2
May ’25US$6.44
US$56.00
+769.6%
14.3%US$64.00US$48.00n/a2
Apr ’25US$9.59
US$54.00
+463.0%
11.1%US$60.00US$48.00n/a2
Mar ’25US$11.36
US$54.00
+375.4%
11.1%US$60.00US$48.00n/a2
Feb ’25US$10.08
US$54.00
+435.6%
11.1%US$60.00US$48.00n/a2
Jan ’25US$12.21
US$52.00
+325.8%
7.7%US$56.00US$48.00n/a2
Dec ’24US$11.52
US$52.00
+351.4%
7.7%US$56.00US$48.00n/a2
Nov ’24n/a
US$52.00
0%
7.7%US$56.00US$48.00US$3.662
Oct ’24US$8.72
US$52.00
+496.3%
7.7%US$56.00US$48.00US$3.912
Sep ’24n/a
US$52.00
0%
7.7%US$56.00US$48.00US$3.352
Aug ’24n/a
US$52.00
0%
7.7%US$56.00US$48.00US$4.232
Jul ’24n/a
US$52.00
0%
7.7%US$56.00US$48.00US$2.492
May ’24n/a
US$490.00
0%
83.7%US$900.00US$80.00US$6.442
Apr ’24US$35.52
US$990.00
+2,687.2%
9.1%US$1,080.00US$900.00US$9.592
Mar ’24US$47.41
US$990.00
+1,988.3%
9.1%US$1,080.00US$900.00US$11.362
Feb ’24US$110.23
US$990.00
+798.1%
9.1%US$1,080.00US$900.00US$10.082
Jan ’24US$104.71
US$990.00
+845.4%
9.1%US$1,080.00US$900.00US$12.212
Dec ’23n/a
US$930.00
0%
3.2%US$960.00US$900.00US$11.522
Nov ’23n/a
US$930.00
0%
3.2%US$960.00US$900.00n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

7D

0.5%

1Y

-5.7%